Understanding the role of C1q+ TAMs in NPC progression underscores the importance of targeting the PI3K/AKT pathway to disrupt the immunosuppressive TME and improve therapeutic outcomes for NPC patients. Here, PIK3CD is linked to nasopharyngeal carcinoma.